Advertisement

Annals of Surgical Oncology

, Volume 19, Issue 7, pp 2420–2420 | Cite as

Erratum to: Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132

  • Dian Wang
  • Qiang Zhang
  • Charles D. Blanke
  • George D. Demetri
  • Michael C. Heinrich
  • James C. Watson
  • John P. Hoffman
  • Scott Okuno
  • John M. Kane
  • Margaret von Mehren
  • Burton L. Eisenberg
Erratum

Erratum to: Ann Surg Oncol (2011) DOI 10.1245/s10434-011-2190-5

In the original article, Fig. 1 contained an error. The bottom left box of the figure should have said “Continued Imatinib 600 mg/day for 24 months” not “Continued Imatinib 600 mg/day for 24 hours.”
FIG. 1

Schematic representation of the trial. SD stable disease, PR partial response, PD progressive disease

The figure is reprinted here correctly.

Copyright information

© Society of Surgical Oncology 2012

Authors and Affiliations

  • Dian Wang
    • 1
  • Qiang Zhang
    • 2
  • Charles D. Blanke
    • 3
  • George D. Demetri
    • 4
  • Michael C. Heinrich
    • 5
  • James C. Watson
    • 6
  • John P. Hoffman
    • 6
  • Scott Okuno
    • 7
  • John M. Kane
    • 8
  • Margaret von Mehren
    • 6
  • Burton L. Eisenberg
    • 9
  1. 1.Medical College of WisconsinMilwaukee USA
  2. 2.Radiation Therapy Oncology Group Statistical CenterPhiladelphia USA
  3. 3.University of British Columbia and British Columbia Cancer AgencyVancouverCanada
  4. 4.Dana-Farber Cancer Institute and Harvard Medical SchoolBoston USA
  5. 5.Portland VA Medical Center and Oregon Health & Science UniversityPortland USA
  6. 6.Fox Chase Cancer CenterPhiladelphia USA
  7. 7.Mayo ClinicRochester USA
  8. 8.Roswell Park Cancer InstituteBuffalo USA
  9. 9.Dartmouth-Hitchcock Medical CenterLebanonUSA

Personalised recommendations